1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Glaukos Acquires DOSE Medical

M&A Deal Summary

Glaukos Acquires DOSE Medical

On June 19, 2019, Glaukos acquired medical products company DOSE Medical for 3M USD

Acquisition Highlights
  • This is Glaukos’ 1st transaction in the Medical Products sector.
  • This is Glaukos’ largest (disclosed) transaction.
  • This is Glaukos’ 1st transaction in the United States.
  • This is Glaukos’ 1st transaction in California.

M&A Deal Summary
Date 2019-06-19
Target DOSE Medical
Sector Medical Products
Buyer(s) Glaukos
Deal Type Add-on Acquisition
Deal Value 3M USD

Target

DOSE Medical

Los Angeles, California, United States
DOSE Medical Corp. is a developer of multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Glaukos

Aliso Viejo, California, United States
Category Company
Founded 1998
Sector Medical Products
Employees995
Revenue 383M USD (2024)
DESCRIPTION

Glaukos is a medical device company focused on developing ophthalmic stents for minimally invasive treatment of patients with glaucoma. Glaukos was founded in 1998 and is based in Aliso Viejo, California.

DEAL STATS #
Overall 1 of 2
Sector: Medical Products M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 2
State: California M&A 1 of 1
Country: United States M&A 1 of 2
Year: 2019 M&A 1 of 2
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-08-07 Avedro

Waltham, Massachusetts, United States

Avedro, Inc. is a hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders and improving vision to reduce dependency on eyeglasses or contact lens. Avedro’s proprietary bio-activated pharmaceuticals strengthen, stabilize, and reshape the cornea to treat corneal ectatic disorders and correct refractive conditions. Avedro, Inc. was founded in 2002 and is headquartered in Waltham, Massachusetts.

Buy -
Mergr

Solution for

Product

Company

Legal